Nate Gray

Nate focuses on representing emerging and growth-stage life sciences and tech companies throughout their life cycles – including corporate formation, venture capital, growth equity and cross-over financings, corporate spinouts, mergers and acquisitions and initial public offerings. His life sciences experience spans a range of biopharmaceutical technologies, tools, diagnostics, digital health and medical device technologies. He also represents private equity firms, venture capital firms and angel investors in investment transactions and portfolio company-related matters.

Nate is passionate about working with companies that are developing technological and scientific innovations that will transform industries and improve lives. He is a dedicated, responsive counselor and advocate for his clients, and seeks to be a long-term partner in the growth and success of his clients’ businesses.

During law school, he was an Edward F. Hennessey Distinguished Scholar, a Paul J. Liacos scholar and an editor for the Boston University Law Review.

Representative matters

Nate’s representative transactions include advising:

• Alamar Biosciences in its $128 million Series C financing, $80 million Series B financing and spinout of Attovia Therapeutics*
• BillionToOne in its initial public offering, $130 million Series D financing, $125 million Series C financing, $48.5 million equity and $35 million debt financing*
• RevenueCat in its $50 million Series C financing and acquisition of Dipsea*
• Monarch Tractor, an electric tractor company, in its $133 million Series C financing*
• Leitmotif in various climate tech investments*
• TeneoTwo in its sale to AstraZeneca for up to $1.27 billion*
• Miroculus, a microfluidics company, in its sale to INTEGRA Biosciences*
• A Fortune 500 biopharmaceutical company in its $30 million private investment in public equity (PIPE) investment in Gritstone bio in connection with a collaboration, license and option agreement to research and develop a vaccine-based immunotherapy treatment for HIV*
• A Fortune 500 biopharmaceutical company in its exclusive option to acquire Tizona Therapeutics, consisting of the acquisition by the company of a 49.9% equity interest in Tizona for $300 million, an option for the company to acquire the remaining equity interests of Tizona for $100 million, and up to $1.25 billion of potential future milestone payments to Tizona equity holders*
• A Fortune 500 biopharmaceutical company in its exclusive option to acquire Pionyr Immunotherapeutics, consisting of the acquisition by the company of a 49.9% equity interest in Pionyr for $275 million, an option for the company to acquire the remaining equity interests of Pionyr for $315 million, and up to $1.15 billion of potential future milestone payments to Pionyr equity holders*

 * Representation handled before joining Cooley.